BIIB34:BVMF
Biogen Inc BDR
184,49Â BRL
0,00%
(0,00) 1D
5 tet, 3:59:13 m.d., GMT-3 · BRL
search
TĂ« gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për BIIB34...
Kapitalizimi i tregut
32,19Â mld
VĂ«llimi mesatar
7,00
VĂ«llimi
0,00
Maksimumi 52-javor
191,00Â BRL
Minimumi 52-javor
128,69Â BRL
Aksionet në qarkullim
147,75Â mln
Numri i punonjësve
8 mijë
Kapitalizimi i tregut
32,19Â mld
VĂ«llimi mesatar
7,00
VĂ«llimi
0,00
Maksimumi 52-javor
191,00Â BRL
Minimumi 52-javor
128,69Â BRL
Aksionet në qarkullim
147,75Â mln
Numri i punonjësve
8 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
AD HOC NEWS
·
9 orë më parë
Biogen reports lupus data while Biogen stock trades at EUR 199.33
Kalkine Media
·
19 orë më parë
Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4
Profili
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Rreth Biogen Inc BDR
Drejtori ekzekutivChris Viehbacher
Punonjësit7,5 mijë
Themeluar më1978
SeliaKembrixh, Massachusetts, Shtetet e Bashkuara të Amerikës
Sektori-
Uebsajtibiogen.com